The SEAS trial

Current Cardiology Reports

Volumn 12, Issue 2, 2010, Pages 122-124

  Carabello, Blase A ^a  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aortic stenosis; Lipids; Statins

Indexed keywords

EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN;

AORTA STENOSIS; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY; DISEASE COURSE; HUMAN; SHORT SURVEY;

ANTICHOLESTEREMIC AGENTS; AORTIC VALVE STENOSIS; AZETIDINES; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SIMVASTATIN;

EID: 77953539404     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0094-9     Document Type: Short Survey

References (16)

1. Bonow R, Carabello BA, Chatterjee K, et al.: ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: A report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Circulation 2006, 114:e84-e231.
2. Rossebo AB, Pederson TR, Boman K, et al.: Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. SEAS Investigators. N Engl J Med 2008, 359:1343-1356.
3. Otto CM, Kuusisto J, Reichenback DD, et al.: Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1993, 90:844-853.
4. Otto CM, Lind BK, Kitzman DW, et al.: Association of aorticvalve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999, 341:142-147.
5. Chandra HR, Goldstein JA, Choudhary N, et al.: Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol 2004, 43:169-175.
6. Stewart BF, Siscovick D, Lind BK, et al.: Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol 1997, 29:630-634.
7. Chui MC, Newby DE, Panarelli M, et al.: Association between calcific aortic stenosis and hypercholesterolemia: Is there a need for a randomized controlled trial of cholesterol-lowering therapy? Clin Cardiol 2001, 24:52-55.
8. Aronow WS, Ahn C, Kronzon I, Goldman ME: Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol 2001, 88:693-695. (Pubitemid 32831111)
9. Pohle K, Maffert R, Ropers D, et al.: Progression of aortic valve calcification: Association with coronary atherosclerosis and cardiovascular factors. Circulation 2001, 104:1927-1932.
10. Novaro GM, Tiong IY, Pearce GL, et al.: Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001, 104:2205-2209.
11. Moura LM, Ramos SF, Zamorano JL, et al.: Rosuvastatin affecting aortic valve endothelium to slow progression of aortic stenosis. J Am Coll Cardiol 2007, 49:554-561.
12. Cowell SJ, Newby DE, Prescott RJ, et al.: A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 2005, 352:2389-2397.
13. Toutouzas K, Drakopoulou M, Synetos A, et al.: In vivo aortic valve thermal heterogeneity in patients with non-rheumatic aortic valve stenosis: First in vivo experience in humans. J Am Coll Cardiol 2008, 52:758-763.
14. Rajamannan NM, Subramaniam M, Stock SR, et al.: Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005, 91:806-810.
15. Garg V, Muth AN, Ransom JF, et al.: Mutations in NOTCH1 cause aortic valve disease. Nature 2005, 437:270-274.
16. Goldbarg SH, Elmariah S, Miller MA, Fuster V: Insights into degenerative aortic valve disease. J Am Coll Cardiol 2007, 50:1205-1213.